Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology

Publication validates the ability of ASPYRE to detect single copies of somatic variants in tissue and plasma

Cambridge, UK, 23 March 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal.  The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at

As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer.

Highlights of the publication include:

  • Ability to detect key actionable genetic markers with single molecule sensitivity 

  • High performance for FFPE tissue and plasma samples, including low DNA input and highly fragmented DNA

  • Demonstrated ability to multiplex, with consistent results for a 47-variant EGFR panel and a 3-variant panel for ERBB2 and ALK fusion (EML4)

  • 100% sensitivity and 99.8% specificity at 0.1% variant allele fraction (VAF)

The publication of data on ASPYRE in the highly respected Scientific Reports Journal is another important step forward in bringing this breakthrough technology to the market. The article provides evidence and validation of our approach to enable many more cancer patients to benefit from precision diagnostics. We are grateful for the support of Agilent, one of Biofidelity’s early investors and collaborators, in helping us to complete this study.
Dr. Barnaby Balmforth
Chief Executive Officer of Biofidelity